Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gene editing
Biotech
GSK won't pick up Wave's genetic disease RNA editor
Wave plans to pursue accelerated approval for WVE-006, an experimental oligonucleotide for alpha-1 antitrypsin deficiency.
Darren Incorvaia
Feb 2, 2026 11:14am
Lilly pens $1.1B pact to work on hearing loss gene editing med
Jan 28, 2026 7:00am
Inside Beam's 'big push' for in vivo gene editing
Jan 21, 2026 7:52am
ARPA-H director eyes future beyond vaccines
Jan 20, 2026 5:00am
Flagship-founded Tessera plans to lay off 90 employees in March
Jan 8, 2026 10:00am
Regeneron inks $150M pact with gene writer Tessera
Dec 1, 2025 11:12am
